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Abstract
Background: Multiple myeloma (MM) is a B-cell malignancy, where malignant plasma cells clonally expand in the bone
marrow of older people, causing significant morbidity and mortality. Typical clinical symptoms include increased serum
calcium levels, renal insufficiency, anemia, and bone lesions. With standard therapies, MM remains incurable; therefore, the
development of new drugs or immune cell-based therapies is desirable. To advance the goal of finding a more effective
treatment for MM, we aimed to develop a reliable preclinical MM mouse model applying sensitive and reproducible
methods for monitoring of tumor growth and metastasis in response to therapy.
Material and Methods: A mouse model was created by intravenously injecting bone marrow-homing mouse myeloma cells
(MOPC-315.BM) that expressed luciferase into BALB/c wild type mice. The luciferase in the myeloma cells allowed in vivo
tracking before and after melphalan treatment with bioluminescence imaging (BLI). Homing of MOPC-315.BM luciferase+
myeloma cells to specific tissues was examined by flow cytometry. Idiotype-specific myeloma protein serum levels were
measured by ELISA. In vivo measurements were validated with histopathology.
Results: Strong bone marrow tropism and subsequent dissemination of MOPC-315.BM luciferase+ cells in vivo closely
mimicked the human disease. In vivo BLI and later histopathological analysis revealed that 12 days of melphalan treatment
slowed tumor progression and reduced MM dissemination compared to untreated controls. MOPC-315.BM luciferase+ cells
expressed CXCR4 and high levels of CD44 and a4b1 in vitro which could explain the strong bone marrow tropism. The
results showed that MOPC-315.BM cells dynamically regulated homing receptor expression and depended on interactions
with surrounding cells.
Conclusions: This study described a novel MM mouse model that facilitated convenient, reliable, and sensitive tracking of
myeloma cells with whole body BLI in living animals. This model is highly suitable for monitoring the effects of different
treatment regimens.
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Introduction
Multiple myeloma (MM) is a B-cell neoplasia characterized by
clonal expansion of malignant plasma cells in the bone marrow
compartment. MM causes significant morbidity and mortality; it
accounts for 1% of all malignant tumors. Among hematologic
malignancies, MM comprises 10–15%, and it causes 20% of
deaths related to cancers of the blood and bone marrow (BM) [1].
The disease mainly occurs in older people, with a median age at
diagnosis of 69 years [2]. In the European Union, the MM
incidence in 2008 was 16,400 for males and 15,600 for females;
this corresponded to an age-standardized incidence rate of 5.4 for
males and 3.9 for females per 100,000 individuals. The age-
standardized mortality rate was 3.3 for males and 2.3 for females
per 100,000 individuals [3].
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MM and its precursor stages originate exclusively from post-
germinal center B-cells, based on the observation that the
immunoglobulin (Ig) sequences in MM plasma cells are somati-
cally hypermutated and remain constant throughout the disease
[4,5]. Chromosomal abnormalities, considered a hallmark of MM,
are present in nearly all patients with MM [6]. The diagnosis of
MM is based on clinical symptoms, including the CRAB criteria:
increased serum calcium levels, renal insufficiency, anemia, and
bone lesions (osteolytic lesions or osteoporosis with compression
fractures). Other clinical symptoms include hyperviscosity, amy-
loidosis, and recurrent bacterial infections. Additionally, patients
commonly exhibit more than 30% clonal bone marrow (BM)
plasma cells and the presence of monoclonal protein is detected in
serum and/or urine [6,7].
Recently, survival for patients with MM has improved with the
introduction of novel agents including thalidomide and its
analogue lenalidomide (immunomodulatory drugs) and bortezo-
mib (a proteasome inhibitor) [7,8]. Nevertheless, patients in the
United States diagnosed with MM between 2001 and 2007 had a
5-year relative survival rate of only 41% [9]. This clearly
underlines the necessity for the development of new drugs and
better treatment strategies. To that end, it would be highly
desirable to develop a MM mouse model that facilitated sensitive,
reliable methodologies for monitoring tumor growth and metas-
tasis in response to different therapies.
At present, several humanized MM models are available,
including the severe combined immunodeficiency SCID-hu/rab
xenograft models. The SCID-hu/rab models were created by
implanting either a human fetal or rabbit bone subcutaneously
into an immunocompromised mouse and injecting primary
human myeloma cells into the bone [10,11]. Other MM models
that use human MM cell lines also rely on immunocompromised
SCID mice as recipients [12]. The drawback of these models is
that it is difficult to create the xenograft mouse, and thus, it is
difficult to obtain a sufficient number of mice to perform the
experiments. Moreover, the use of immunocompromised mice
precludes studies on the effects of potential immune system-tumor-
drug interactions.
Several spontaneously occurring murine MM cell lines (5T cell
lines) have also been employed; these cells can be inoculated into
immunocompetent C57BL/KaLwRijHsd mice [13,14]. Addition-
ally, the mineral oil-induced plasmacytoma cell (MOPC-315) line
has proven useful in studying immune–tumor cell interactions and
drug testing in models where these murine MM cells were injected
either intravenously or subcutaneously [15–19]. The readout of
tumor burden is typically based on parameters from histology or
the levels of paraprotein in the serum [14]. However, histology
requires sacrificing the mice, and paraprotein levels do not provide
information about tumor localization.
The present study aimed to establish an orthotopic MM mouse
model injected with luciferase (luc+) expressing MOPC-315 cells to
facilitate non-invasive, in vivo, tumor growth monitoring. Moni-
toring was performed with a light-sensitive charge-coupled device
(CCD) camera system [20–23]. This MM model mimicked the
human disease in the late stages of MM progression and allowed
reliable, sensitive detection of the response to therapy.
Materials and Methods
Ethics Statement
All experiments were performed according to the German
regulations for animal experimentation. The study was approved
by the Regierung von Unterfranken as the responsible authority
(Permit Number 55.2-2531.01-76/10 and -103/11).
Mice
All experiments were performed with female BALB/c (haplo-
type H-2d) mice, 8–10 weeks old (Charles River, Sulzfeld,
Germany).
MOPC-315.BM luc+ Cell Line and Culture Conditions
We obtained mouse myeloma MOPC-315 cells [24], an in vitro-
adapted cell line, from ATCC (Manassa, VA). The MOPC-315.4
cell line was derived by repeated subcutaneous (s.c.) injections of
MOPC-315 cells into BALB/c mice [25]. The MOPC-315.4 cells
(26106) were then injected intravenously (i.v.) into BALB/c mice.
Tumor cells were flushed from the femurs of paraplegic mice, then
cultured in vitro, and re-injected i.v. After nine in vivo/in vitro cycles,
a cell line with bone marrow tropism, MOPC-315.BM, was
obtained (B. Bogen and co-workers). MOPC-315.BM cells were
co-transfected with the pGL3-Control plasmid that carried the
firefly luciferase (luc) gene (Promega) and the pcDNA 3.1 plasmid
that carried the neomycin resistance gene (Invitrogen). Transfect-
ed cells were cloned by limiting dilution, resulting in the MOPC-
315.BM luc+ cell line [26].
MOPC-315.BM luc+ cells were cultured in RPMI, supplement-
ed with 10% FCS, 1% penicillin and streptomycin, and 1% L-
glutamine (Invitrogen, Darmstadt, Germany). Cells were main-
tained in a humidified incubator at 37uC and 5% CO2.
Drug Preparation
Melphalan was dissolved in 100% ethanol to a concentration of
20 mM. Based on the individual weight of each mouse, the
appropriate amount of melphalan was diluted in 100 ml phosphate
buffered saline (PBS) to achieve a final melphalan concentration of
5 mg/kg body weight for each intraperitoneal (i.p.) injection
[27,28]. Vehicle-injected control animals received corresponding
amounts of ethanol; untreated mice were not injected.
Multiple Myeloma Tumor Model and Drug Treatment
MOPC-315.BM luc+ cells (H-2d haplotype) were suspended
(105 cells) in PBS and injected i.v. via the lateral tail vein into
BALB/c (H-2d) mice. 19 days after the injection of the MM cell
line MOPC-315.BM luc+, animals were imaged with in vivo
bioluminescence (BLI). After BLI, the mice were treated with
melphalan (day 0 of treatment). Mice also received melphalan on
days 3, 7, and 11 of treatment. The BLI measurement on day 0
represented untreated animals with the initial tumor burden
before drug intervention. BLI signals measured on day 0 of
treatment were set to 1, and all subsequent BLI measurements
were expressed as the fold change relative to this initial signal.
Bioluminescence Imaging (BLI)
BLI was performed on mice with an IVIS Spectrum (Caliper-
Xenogen, Alameda, CA, USA) as previously described [21].
Briefly, mice were anesthetized i.p. with a mixture of ketamine
(100 mg/kg) and xylazine (10 mg/kg) in PBS. Luciferin (150 mg/
kg) was coinjected, and BLI measurements were started exactly
10 min later. To confirm localization of light emitting foci, at the
end of the experiment mice were then euthanized, organs were
prepared, and ex vivo imaging was started exactly 10 min after the
injection. Imaging data was analyzed with Living Image 4.0
(Caliper-Xenogen, Alameda, CA, USA) and Prism 5 software
(GraphPad, La Jolla, CA, USA).
Untreated or vehicle-treated mice were analyzed on days 11,
19, and 33 after the MOPC-315.BM luc+ cell injection to
determine the average number of skeletal foci per mouse and the
percentage of mice that displayed signals in liver and spleen.
BLI Based Multiple Myeloma Mouse Model
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Individual skeletal spots and signals from the spleen and liver were
visually determined on BLI images acquired from ventral and
dorsal views.
Organ Preparation and Flow Cytometry Analysis
At 42 days after the i.v. injection of 16105 MOPC-315.BM luc+
cells, mice were euthanized, and spleen and femur/tibia BM cells
were harvested for flow cytometry analysis. Spleens were passed
through a 70 mm cell strainer (BD Biosciences, Bedford, MA,
USA) to create a single cell suspension, and erythrocytes were
lysed. Femur and tibia BM were flushed by ejecting PBS from a
syringe. Cells were stained with the following fluorophore-
conjugated antibodies (clones): anti-CD4 APC-Cy7 (GK1.5);
anti-CCR7 APC (4B12); anti-CD62L APC-Cy7 (MEL-14); anti-
a4b7 PE (DATK32); anti-a4 (CD49d) Alexa647 (RI-2); anti-
CXCR3 APC (CXCR3-173); anti-CD44 PE (IM7); anti-CD4 PE
(RM4-5) (all from Biolegend); anti-CCR2 APC (475301) (R&D
Systems); anti-CXCR4 PE (2B11) or anti-CXCR4 APC (2B11)
(from eBioscience), and anti-CD138 Biotin (281-2) (from BD
Pharmingen). Biotinylated antibodies were detected with strepta-
vidin eFluor 450 (from eBioscience) or Alexa 488 (from
Invitrogen). Dead cells were excluded with propidium iodide
staining.
Flow cytometry was performed on a FACS Canto II (BD,
Heidelberg, Germany), and data was analyzed with FlowJo (Tree
Star, Ashland, OR, USA) and Prism 5 software (GraphPad, La
Jolla, CA, USA). MOPC-315.BM luc+ cells were identified by first
gating on CD138+CD4+ double-positive cells; both markers were
constitutively expressed in both MOPC-315 and MOPC-315.BM
luc+ cells. Within this gate, the mean fluorescence intensity (MFI)
from antibodies bound to homing receptors was determined
relative to the fluorescence minus one (FMO) sample (unstained
cells). The FMO was used to determine the percentage of cells that
expressed the homing receptors or the fold change in expression
[29]. MFI were also determined for cell surface markers that
displayed gradual changes in expression, including CXCR4,
CXCR3, CD44, CCR2, and CCR7.
To identify a4b1+ and a4b7+ MOPC-315.BM luc+ cells, gates
for the homing receptors, a4b7 and a4, were set based on the
FMO method (Figure S1) [29]. The simultaneous staining of
a4b7 and a4 allowed identification of a4b1+ cells [30]. The a4
subunit must associate with either the b1 or the b7 integrin subunit
to form a functional receptor; therefore, cells that stained for a4,
but not a4b7, were considered a4b1 positive.
Fluorescence-activated Cell Sorting (FACS)
To select MOPC-315.BM luc+ cells that expressed either low or
high levels of CXCR4, cells were stained with anti-CXCR4 APC
(2B11; eBioscience). Cells were sorted on a FACS Aria III (BD,
Heidelberg, Germany) and the 10% with the lowest (CXCR4low)
and 10% with the highest (CXCR4high) signals were isolated.
Subsequently, 56105 CXCR4high or CXCR4low MOPC-315.BM
luc+ cells were injected i.v. into female BALB/c mice. After 10
days, mice were imaged with BLI, sacrificed, and spleen and
femur/tibia marrow cells were extracted for FACS analysis to
determine CXCR4high and CXCR4low expression. Additionally,
cells from each sorted fraction of CXCR4low and CXCR4high cells
were maintained in culture for 2 days, and then reanalyzed for
CXCR4 expression with the same anti-CXCR4 antibody that was
used for cell sorting.
Histology
For histological examination, samples were fixed in 4% neutral-
buffered formalin or embedded in Tissue-Tek OCT compound
and frozen for storage. Subsequently, bones were decalcified for
72 h in formic acid (Merck, Darmstadt, Germany) and then
embedded in paraffin. Samples were cut into sections (2 mm),
stained with hematoxylin and eosin (H&E), and reviewed by an
experienced pathologist (A.M.). In spleen and BM biopsies the
total percentage of tumor infiltration was determined. In liver and
lung samples, the average number of tumor cells was determined.
In both cases, cells were counted under a microscope, in ten high
power fields (HPF, magnification 6400). Representative images
were obtained with a DP26 camera (Olympus, Hamburg,
Germany) and cellSens Entry 1.5 Software, version XV 3.5.
Frozen sections were fixed in acetone and subsequently stained
with anti-CD31 Alexa647 (390, Biolegend), anti-CD4 Alexa488
(RM4-5, Biolegend), and anti-IgA Biotin (11-44-2, eBioscience),
followed by Streptavidin Alexa546 (Invitrogen). Nuclei were
stained with 49,6-diamidino-2-phenylindole (DAPI). Images were
obtained with an AxioCamMR3 camera, mounted on an Axio
Imager.Z1 microscope (Carl Zeiss, Jena, Germany) equipped with
AxioVision software. The objective was a 406/1.30 oil EC Plan-
Neofluar.
ELISA
Mouse blood samples were obtained from tail veins. After
clotting, the blood was centrifuged, and the serum was removed
and stored at 280uC until further use. The MOPC-315 idiotype-
specific, secreted IgA M315 protein [25] was detected by ELISA.
Briefly, 96 well ELISA plates were coated with 2 mg/ml idiotype-
specific antibody (clone AB2.1.-4) in PBS, and plates were
incubated overnight at 4uC. Duplicate serum samples were diluted
1:100 in ELISA buffer. An M315 protein standard was prepared
at 400 ng/ml and several 2-fold serial dilutions (ranging from 400
to 0.39 ng/ml). Samples and standards were added to the plates
and incubated for 2 h at 37uC. Three washes with ELISA wash
buffer (Biolegend) were performed. Biotinylated, rat, anti-mouse
IgA (1 mg/ml; clone C10-1, BD Pharmingen) was added for 1 h at
37uC. Three washes with ELISA wash buffer were performed.
Then, streptavidin-conjugated alkaline phosphatase (GE Health-
care), diluted 1:3000 in ELISA buffer, was added, and the
incubation continued for 1 h. Three washes with ELISA wash
buffer were performed. Next, phosphatase substrate (Sigma-
Aldrich) was added at 1 mg/ml in substrate buffer (97 ml
diethanolamine, 800 ml distilled water, 101 mg MgCl266H2O,
200 mg sodium azide, add 10 ml 37% HCl and fill up with
distilled water to 1 l). After a 25-min incubation at room
temperature, absorbance was measured at 405 nm. The data
was analyzed with Prism 5 software (GraphPad, La Jolla, CA,
USA). Serum was collected from melphalan-treated and vehicle
control mice after 14 days of treatment to compare IgA M315
serum levels to the whole body BLI signal (ventral signal+dorsal
signal). For long-term observations, untreated mice were regularly
bled for serum collections and simultaneously underwent BLI from
ventral and dorsal views.
Statistics
Statistical analysis was performed with InStat 3.00 or Prism 5
software (GraphPad, La Jolla, CA, USA). To determine tumor
growth over time, at each timepoint, BLI data were compared
among the three mouse groups with a two way ANOVA and
Tukey post test for multiple comparisons. Adjusted p values are
stated.
The Kruskal-Wallis test and Dunn post test were applied for
comparisons among the three groups. A two tailed t-test was used
to analyze the statistical significance of differences between two
BLI Based Multiple Myeloma Mouse Model
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groups. All measurements are expressed as the mean with standard
deviation (SD), unless stated otherwise.
Results
Effective Migration of MOPC-315.BM luc+ Myeloma Cells
to Hematopoietic Compartments
To investigate the behavior and biology of MM cells in the
context of the living organism luciferase expressing MOPC-
315.BM luc+ cells were injected (i.v.) into BALB/c recipients. First,
MM cell homing patterns, expansion, and dissemination were
tracked with sequential, non-invasive, BLI. At 11 days after the
injection, the MOPC-315.BM luc+ cells in all recipients emitted
discrete signals (Figure 1A). Light-emitting foci appeared most
frequently in the skull, vertebrae, sternum, femur, tibia, and other
parts of the skeleton. Mice exhibited an average of 1.6 skeletal
bioluminescent foci on day +11 (Figure 1B), and a signal was
detected in the spleen in 57% of mice (Figure 1C) (n = 51, 3
independent experiments). Therefore, early homing sites of
MOPC-315.BM luc+ cells primarily comprised the hematopoietic
compartment.
From the initial proliferation hot spots, MM cells metastasized
to other skeletal areas (Figure 1A arrows). Between days +19
(n = 56, 3 independent experiments) and +33 (n= 25, 3 indepen-
dent experiments), the average number of skeletal MM foci
increased from about 3 to over 10 per mouse (Figure 1B). After
day +19, signals were detected in the spleen in nearly all mice
(Figure 1C). Of note, signals were detected in the liver in 90% of
mice on day +11; however, unlike the skeletal or splenic foci, the
liver signals remained comparatively low-intensity, and they did
not increase in signal strength throughout the experiment
(Figure 1A). Four representative spots (Figure 1A) were marked
on day 11 to determine whether the increase in tumor burden over
time was due to growth of an initial focal tumor or proliferation
and dissemination of multiple myelomas. The signal intensities
were measured for each representative spot over time (Figure 1D).
Spots 1 and 2 represented signals in the femur, spot 3 was in the
spleen, and spot 4 was in a shoulder bone. Indeed, local signals
increased at these four spots over time (Figure 1D). This initial,
persistent, focal tumor growth was followed by subsequent
spreading to distant skeletal regions, which resulted in a steady
increase in the total luciferase signal (Figure 1E). Bone
remodeling and osteolytic lesions were detected in .35% of
animals at 42 days after MM injection. For example, corticalis
destruction was observed in the neck of the femur (Figure 1F).
MOPC-315.BM luc+ Cells Express Receptors for Bone
Marrow Homing and Retention
The results indicated strong tropism of MOPC-315.BM luc+
myeloma cells towards the hematopoietic compartment. Thus,
cells were investigated to identify homing receptors that previously
showed efficient recruitment to BM niches. A panel of surface
markers was tested on MOPC-315.BM luc+ cells extracted from
BM and spleen at 42 days after MM injection (n = 10, two
independent experiments) (Figure 2A). For comparison the
surface markers were also tested in MOPC-315.BM luc+ cells
maintained in from tissue culture (n = 3; 4 independent measure-
ments).
Expression of a4b1 integrin was detected in 80% of the in vitro
cells, in 91% of the MOPC-315.BM luc+ cells reisolated from the
BM, and in 73% of cells reisolated from the spleen (p,0.05)
(Figure 2B). Integrin a4b1 facilitates transendothelial migration
of MM cells into the BM. Integrin a4b1 can be upregulated by the
interaction between CXCR4 and its ligand, stromal cell-derived
factor-1 (SDF-1) [31,32], a chemoattractant constitutively pro-
duced by BM stromal cells. Thus, MM cells that express CXCR4
are recruited and retained in the BM [32]. Of note, MOPC-
315.BM luc+ cells from the spleen exhibited downregulated
CXCR4 expression compared to those isolated from the BM
(p,0.05) and those maintained in cell culture (p,0.01)
(Figure 2C).
The CD44 receptor mediates MM cell binding to hyaluronic
acid on the BM endothelium; this interaction supports BM
homing and invasion [33,34]. Overall CD44 expression was high
in MOPC-315.BM luc+ cells, both in vitro and in different
compartments in vivo. Nevertheless, MOPC-315.BM luc+ cells
isolated from the BM expressed significantly higher CD44 levels
than those in the spleen (p,0.01) (Figure 2D).
CXCR4low and CXCR4high expressing MOPC-315.BM luc+
cells were tested for preferential homing to the spleen or the BM,
which might explain the result shown in Figure 2C. We injected
56105 of either CXCR4low or CXCR4high MOPC-315.BM luc+
cells into syngeneic mouse recipients (n = 4 each). Interestingly,
when these two distinct populations of CXCR4 expressing
MOPC-315.BM luc+ cells were maintained for 2 days in cell
culture, both populations regained the initial CXCR4 expression
profile (Figure 2E). Consistent with that finding, after 10 days
in vivo, non-invasive BLI (Figure 2F) showed that signals for both
sorted populations were detected in both the spleen and the BM
compartment. Thus, the CXCR4 expression level of i.v. injected
cells did not govern homing to the spleen or BM. However, in vivo
BLI showed that the CXCR4low MOPC-315.BM luc+ cells
proliferated more than the CXCR4high cells. After BLI, animals
were euthanized, and cells from the spleen, left femur/tibia, and
right femur/tibia were harvested separately for FACS analysis.
The percentage and the absolute numbers of CD138+CD4+ were
determined for each femur/tibia ( = BM) and the spleen. The
ratios of spleen/BM signals showed that there was no difference in
homing preference between CXCR4low and CXCR4high MOPC-
315.BM luc+ cells (Figure 2G). This corroborated the in vivo BLI
results. We also compared the MFIs of freshly sorted CXCR4low
and CXCR4high MOPC-315.BM luc+ cells with the MFI of MM
cells extracted from femur/tibia and from the spleen 10 days after
injection (Figure 2H). This showed that CXCR4 expression
dynamically changed in vivo.
The other homing receptors tested, for example a4b7 integrin,
showed low expression (,10% of MOPC-315.BM luc+ cells)
in vitro and levels decreased in vivo (Figure S2A). However,
because MOPC-315.BM luc+ cells exhibited strong homing to
the spleen, we tested the expression of CD62L and CCR7
receptors, which are involved in homing to secondary lymphoid
organs. CD62L expression was expressed at low levels on MOPC-
315.BM luc+ cells prior to injection; after injection, expression
increased in cells from the spleen, but not in cells from the BM
(Figure S2B). CCR7 was not expressed at significant levels, either
before or after injection (Figure S2C). Finally, CXCR3 and
chemokine receptor 2 (CCR2), important for MM progression,
dissemination [35], and BM homing [36] were not significantly
expressed on the cells analyzed (Figure S2D and S2E).
Attenuation of Myeloma Disease Progression in Mice
Treated with Melphalan
To test this mouse model for reliable detection of changes in
tumor load with in vivo imaging, we treated tumor-bearing mice
with the alkylating agent, melphalan, a well-established treatment
for MM in humans. We included mice treated with melphalan
(dissolved in ethanol; n = 9), a vehicle-treated control group
(ethanol only; n = 13), and untreated controls (n = 14). The
BLI Based Multiple Myeloma Mouse Model
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treatment began 19 days after the MOPC-315.BM luc+ cell
injection, when the disease was fully established (day 0 of
treatment). Mice were treated with melphalan on days 0, 3, 7,
and 11 of treatment, and sacrificed for histology on day 14 of
treatment (Figure 3A). Images (Figure 3B) show ventral (left)
and dorsal (right) views of two mice representative of each group;
BLI was performed immediately before the first treatment (day 0
of treatment), on day 7 of treatment, and immediately before
sacrificing the animals (day 14 of treatment). BLI signals markedly
increased in vehicle controls and untreated animals, but no
significant increases were noted in mice treated with melphalan
(Figure 3C). Starting on day 10 of treatment, significant
differences between groups were detected in both ventral
(untreated vs. melphalan p,0.0001, vehicle vs. melphalan
p= 0.0032) and dorsal (untreated vs. melphalan p= 0.0006,
vehicle vs. melphalan p= 0.0024) images. No significant differ-
ences were detected between vehicle-treated and untreated mice.
Additionally, we detected new skeletal tumor foci from
disseminating MM cells in untreated and vehicle-treated mice;
in contrast, melphalan-treated mice showed little or no MM
dissemination (Figure 3B). Indeed, the numbers of visible skeletal
tumor foci had considerably increased from day 0 to day 14 of
treatment in both control groups. In contrast, melphalan-treated
Figure 1. Engraftment and growth dynamics of MOPC-315.BM luc+ myeloma cells in vivo. BALB/c wild type mice were injected with
16105 MOPC-315.BM luc+ cells via the tail vein. Tumor growth and spread was regularly monitored by BLI. (A) BLI images of one representative
mouse at indicated time points after MM injection from ventral (top) and dorsal (bottom) view. Additional emerging tumor foci over time are marked
with black or white arrows. (B) Number of skeletal spots per mouse on days +11 (n = 51), 19 (n = 56) and 33 (n = 25) and (C) percentage of mice
presenting signals from liver and spleen. (D) Quantification of single tumor foci over time as marked in (A): 1 and 2= BM compartment of femur/tibia,
3 = spleen, 4 = BM compartment of shoulder. (E) Absolute signal quantification by whole body BLI from ventral and dorsal views. (F) Representative
osteolytic lesion in the neck of femur 42 days after MM injection. Corticalis is marked as c which is destroyed (arrow) by MOPC-315.BM luc+ cells
marked with T. Original magnification 40X, scale bar is 200 mm. Insert: original magnification 200X, scale bar is 100 mm.
doi:10.1371/journal.pone.0052398.g001
BLI Based Multiple Myeloma Mouse Model
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Figure 2. Flow cytometric measurement of surface receptors associated with BM homing and infiltration of myeloma cells. BALB/c
wild type mice were injected with 16105 MOPC-315.BM luc+ cells via the tail vein. (A) 42 days after MM injection mice showed high BLI signals from
hematopoietic compartments such as femur/tibia and spleen. Shown are two representative mice from ventral and dorsal view immediately before
cells from BM and spleens were harvested for flow cytometry. (B–D) Besides BM and spleen derived MM cells, we also analysed MOPC-315.BM luc+
cells from culture. Dead cells were excluded by propidium iodide staining and MOPC cells identified as CD138+CD4+ double positive cells. (B) a4b1
integrin positive MOPC-315.BM luc+ cells were identified by flow cytometry as a4+ (CD49d+) and a4b72. Representative FACS plots and the
corresponding graph are shown, stating the frequency within CD138+CD4+ MOPC-315.BM luc+ cells expressing a4b1. For CXCR4 (C) and CD44 (D)
representative histograms for each organ and cell line, including unstained fluorescence minus one (FMO) sample are displayed. Corresponding
graphs state the fold difference in mean fluorescence intensity (MFI) related to the unstained FMO sample. BM and spleen: two independent
experiments, n = 10, cells from cell culture: n = 4 for CXCR4 and CD44, n = 3 for a4b1. * indicates p,0.05 and ** indicates p,0.01 as determined by
Kruskal-Wallis test with Dunn post test. (E) MOPC-315.BM luc+ cells were sorted for CXCR4low and CXCR4high expression. After 2 days in cell culture
sorted cells regained the original CXCR4 expression level of the cell line. (F) 56105 sorted cells were i.v. injected into 4 female BALB/c mice each and
BLI from ventral, lateral and dorsal was performed 10 days later. Sorted CXCR4low as well as CXCR4high CXCR4 cells readily homed to the BM
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compartment as well as to the spleen. (G) After BLI the mice were sacrificed, cells from left and right femur/tibia (separately) and the spleen extracted,
and percentage as well as absolute numbers for CD138+CD4+ MM cells determined. From these values a ratio of spleen/BM was calculated to
determine the homing capacity of the sorted populations. (H) Comparison of CXCR4 expression levels of sorted CXCR4low and CXCR4high cells
immediately before injection and MM cells from BM and spleen after 10 days in vivo revealed a dynamic CXCR4 regulation.
doi:10.1371/journal.pone.0052398.g002
Figure 3. Detection of residing MOPC-315.BM luc+ cells and in vivo monitoring of reduced myeloma progression due to melphalan
treatment. BALB/c wild type mice were injected with 16105 MOPC-315.BM luc+ cells via the tail vein. On day +19 after inoculation, tumors were
established in all mice and readily detected by BLI. Then treatment was started ( = day 0 of treatment). Mice received 5 mg/kg melphalan (n = 9, two
independent experiments) or mock treatment (vehicle control, n = 13, three independent experiments) intraperitoneally. One control group of MOPC-
315.BM luc+ tumor bearing mice did not receive any treatment (untreated control, n = 14, three independent experiments). (A) Schematic study
design, indicating treatment time points in respect to time after MM injection and end of experiment. Red arrows pinpoint melphalan treatment. (B)
BLI images of two representative mice per group at selected time points in ventral (left) and dorsal (right) view. (C) Quantification of bioluminescence
signal intensities over time from ventral or dorsal. Signals at day +19 were set as starting point and the following measurements were calculated as
fold change of this initial signal intensity. Mice were treated at time points as indicated by arrows. Significant difference between melphalan treated
mice vs vehicle control or vs untreated animals starting on day 10 of treatment for both, ventral (untreated vs melphalan p,0.0001, vehicle vs
melphalan p= 0.0032) and dorsal (untreated vs melphalan p= 0.0006, vehicle vs melphalan p= 0.0024). (D) Quantification of skeletal tumor foci in
untreated, vehicle control and melphalan treated mice on day 0 and 14 of drug treatment.
doi:10.1371/journal.pone.0052398.g003
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mice showed few or no new disseminations, and some exhibited a
reduced number of tumor foci (Figure 3D).
Two mice in the untreated control group developed paralysis in
the hind legs at 30 and 32 days after injection of MOPC-315.BM
luc+ cells. This was due to tumor growth in the spine, which
caused nerve compression.
Ex vivo BLI was performed to confirm the in vivo BLI signal
localizations assigned to organs or bones. Mice were sacrificed on
day +14 of treatment for ex vivo imaging. Organs that displayed
in vivo signals (liver, spleen, and femur/tibia) were separated from
organs that did not show in vivo signals (lungs). The signals detected
with ex vivo BLI were consistent with those detected in vivo in liver,
spleen, and femur/tibia (Figure S3). In contrast, ex vivo imaging
revealed a signal in the lungs that was absent on in vivo BLIs
(Figure S3). Similarly, ex vivo imaging supported the findings from
in vivo BLI for melphalan-treated mice. Lower signal intensities
were found with treatment than without treatment.
Histological Examinations Confirmed in vivo BLI
Measurements of Response to Drug Treatment
To resolve MOPC-315.BM luc+ cells within organs and to
confirm measured BLI signals on a cellular basis, histological
sections were evaluated by an experienced, unbiased pathologist.
MOPC-315 luc+ cells were morphologically distinct from other
cell types with H&E stain; therefore no additional stain was
necessary (Figure 4A). MOPC-315.BM luc+ cells were observed
in the spleen and femur/tibia BM. In contrast, in liver and lungs,
myeloma cells were localized in blood vessels, and did not invade
tissues (Figure 4A, magnified inserts and Figure S4). This
suggested that the weak in vivo BLI signals from the vascularized
liver originated from circulating MM cells that passed through the
organ during the signal acquisition.
To confirm the significant differences among the three
treatment groups, single MM cells were counted in liver and
lung; in the spleen and BM, the percentage of MM cell infiltration
was evaluated, because the large numbers of MM cells made
counting unreliable. Compared to untreated controls, melphalan-
treated mice clearly exhibited less infiltration in spleen, in BM
(Figure 4B), and in the vasculatures of liver and lung (Figure 4C).
This reduced circulation of MM cells in melphalan-treated mice
might explain the reduced dissemination detected with in vivo BLI
(Figure 3D).
The histological examination of the liver did not reveal any
progressive disease in melphalan-treated mice. However, in the
vehicle-treated group, liver infiltration was observed; in 2 out of 10
mice, very small tumors were found (less than 1 mm in diameter).
In the untreated group, a liver tumor of 15 mm in diameter was
observed in 1 of 9 animals. In quantifications of liver infiltration,
histological liver data from the animals with liver tumors were
excluded (Figure 4C). Most likely, the melphalan treatment
inhibited the formation of tumors in the liver.
Serum M315 IgA Levels also Verified Treatment Response
Measured with Non-invasive BLI
The non-invasive BLI data was also verified by ELISA
measurements of M315 IgA immunoglobulin secreted by
MOPC-315.BM luc+ cells [37]. The measurement of MM-derived
Ig is widely used in mouse models to determine tumor load
[38,39]. We tested whether MOPC-315-idiotype-specific IgA
(M315 IgA) correlated with tumor load after drug treatment.
Both in vivo BLI and histology indicated significantly less tumor
burden in melphalan-treated vs. vehicle-injected control mice. On
day 14 of treatment, serum was collected from representative mice
from the vehicle and melphalan treatment groups, and non-
invasive BLI was performed in parallel (Figure 3A). M315 IgA
levels were significantly reduced in melphalan-treated mice (n = 5)
compared to vehicle-treated control animals (n = 5) (two-tailed p-
value 0.0171). This was supported by the simultaneously obtained
in vivo BLI data, which showed a similar significant difference (two-
tailed p-value 0.0221) (Figure 5A).
Five untreated mice were monitored over an extended time
period with simultaneous serum M315 IgA and BLI measure-
ments (Figure 5B). In general, the M315 IgA data correlated with
the BLI data; three mice with high BLI signals (ventral+dorsal) also
showed high M315 IgA levels (Figure 5C–E); two mice with low
BLI signals also had comparatively low M315 IgA levels
(Figure 5F, G). In all 5 animals, M315 IgA was clearly detected
on day +24, and it steadily increased until the last measurement on
day +43.
In mice, the half-life of IgA is 24 h [40]; however, in humans,
the half-life is considerably longer, up to 4–6 days [41]. Therefore,
in humans, M315 IgA ELISA measurements might slightly
overestimate the actual tumor load due to accumulation. In
contrast, BLI can detect the MM load in real time. Furthermore,
the first BLI signals were detectable on day +9 after MM injection,
when M315 IgA levels were at background levels. This indicated
that BLI was more sensitive than serum M315 IgA for the
detection of MM in this mouse model.
Discussion
In this study, we created a reliable, highly reproducible,
orthotopic, MM mouse model to facilitate in vivo preclinical drug
testing. Moreover, because this model retained a complete,
unmanipulated immune system, we believe that this model will
be also suitable in future studies of immune cell–tumor cell
interactions in various settings; for example, in studies of graft-
versus-myeloma effects after allogeneic stem cell transplantation.
To facilitate sensitive, non-invasive monitoring of tumor growth
and localization, we transfected freshly isolated MOPC-315.BM
cells with luciferase before injection into syngeneic recipients. This
allowed in vivo BLI detection of MM cells throughout the body.
The initial tumor inoculation and subsequent outgrowth revealed
striking similarities to the progression and localization observed in
the human disease. We detected typical multifocal growth in
hematopoietic compartments involving the skeleton and spleen.
BLI offered the ability to detect new tumor foci, and to quantify
the growth of single spots within the whole mouse. This important
technique also allowed assessments of the impact of a therapy on
the overall tumor burden and the changes in single foci. Thus, BLI
can be used to determine the potential of new drugs on tumor
metastases and disease involvement in different organ compart-
ments. Due to the high sensitivity of BLI measurements, we could
detect small increases in tumor burden throughout the body. This
feature is important for assessing the efficacy of drug treatments or
for detecting minimal residual disease.
Several studies have previously demonstrated strong correla-
tions between non-invasive BLI data and the actual tumor load
measured with traditional methods, including serum markers or
histopathology [42,43]. In this study, we also demonstrated the
reliability of in vivo BLI in the MM mouse model. Differences in
tumor growth were achieved by treating some mice with
melphalan, the treatment of choice for patients with MM
[44,45]. Our results with in vivo BLI showed clear differences
between treated and untreated groups. Melphalan reduced the
tumor burden and diminished the tumor spread throughout the
body. Subsequent ex vivo imaging and, more importantly,
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Figure 4. Histopathological analysis of organs from melphalan, vehicle control treated and untreated mice confirms in vivo BLI
data. (A) Representative H&E stainings from organs harvested at day +33 after tumor inoculation from the different treatment groups. The
hematopoietic compartments BM and spleen displayed clear infiltration of MOPC-315.BM luc+ cells, while MOPC-315.BM luc+ cells in lung and liver
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PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e52398
histological analyses validated the in vivo BLI data. These analyses
demonstrated that this model was suitable for non-invasive
measurements of tumor load and spread. Thus, this model
permitted long-term tracking of MM cells with high sensitivity in
an anatomical context, and obviated the need to euthanize mice.
This model also resembled human MM in the detectable
secretion of IgA immunoglobulin from MOPC-315.BM luc+ cells.
The idiotype-specific, M315 IgA protein was detectable within the
total IgA in mouse serum. In addition to histology, serum
immunoglobulin measurements are widely used to determine
tumor load in mouse models [38,39]. In this mouse model, the
ELISA measurement of idiotype specific IgA correlated with BLI
measurements of tumor burden. With both methods, significant
differences in tumor load were detected between melphalan-
treated and untreated mice. Moreover, the correlation between
M315 IgA and BLI measurements was consistent over 43 days.
However, the BLI signal was detected earlier (within 9 days after
MM injection) than the change in M315 IgA above background.
resided within the blood vessels as indicated by arrows. Scale bar is 50 mm for all shown sections (original magnification 200X/0.70 NA) and 20 mm for
inserts (original magnification 400X/0.85 NA). (B) Determination of the percentage of MOPC-315.BM luc+ cells within BM and spleen and (C) number
of cells per high power field (HPF) in lung and liver significantly correlates with the melphalan treatment and thereby confirms in vivo and ex vivo
imaging data.
doi:10.1371/journal.pone.0052398.g004
Figure 5. Tumor detection by in vivo BLI correlates to M315 IgA serum measurement by ELISA. (A) M315 serum levels of melphalan
treated (n = 5) and vehicle control (n = 5) on day 14 of treatment and simultaneous BLI measurement of the same mice. The treatment schedule is
depicted in Figure 3A. Measurement of idiotype specific M315 IgA significantly differed between the groups (two-tailed p value 0.0171) as it did with
BLI (ventral+dorsal signal) (two-tailed p value 0.0221). (B) Scheme indicating time points for BLI measurement and serum collection for data
presented in (C–G). (C–G) Idiotype specific M315 IgA serum levels of 5 untreated mice constantly increased over time correlating with progressing
tumor burden as measured with BLI (ventral+dorsal signal). Of note, BLI measurements provided signals in early disease stages starting from day +9,
whereas M315 IgA levels were not detectable at this time point. The left y-axis displays BLI signal intensity (black circles, solid lines); the right y-axis
displays serum M315 IgA (red triangles, dashed lines).
doi:10.1371/journal.pone.0052398.g005
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Additionally, BLI provided important information about tumor
cell location, which cannot be measured with ELISA.
A strong correlation was also found between in vivo BLI and flow
cytometry analyses (Figure S5).
The MOPC-315.BM luc+ cells showed similarity to the human
MM disease in the strong homing to hematopoietic compartments.
When, cells were tested for receptors associated with this homing
pattern, we found that MOPC-315.BM luc+ cells expressed the
MM-associated surface marker CD138. This molecule is typically
expressed in human MM cells. Interestingly, the MOPC-315.BM
luc+ cells also displayed the surface marker CD4, which is a typical
marker for T cells, but not for B cells. However, some studies have
reported cases where human MM cells acquired T cell-associated
markers [46]. CD4 expression was also found in MOPC-315
parental cells obtained from the ATCC (Figure S6). Therefore,
we concluded that this marker was not involved in the homing of
MOPC-315.BM luc+ cells into hematopoietic compartments. Our
results also showed that CXCR4 was expressed on the MOPC-
315.BM luc+ cell line in vitro and in vivo. CXCR4 binds to the
chemokine, SDF-1, produced by BM stromal cells, which triggers
MM cell migration towards the BM [47]. In vitro cultured MOPC-
315.BM luc+ cells expressed higher CXCR4 levels than the cells
reisolated from BM and spleen. This might explain the strong BM
tropism of the cell line upon i.v. injection. A similar finding was
reported in patients with MM; circulating MM cells displayed
higher CXCR4 levels than cells isolated from the BM [47].
Furthermore, previous studies on human and murine myeloma
cells showed that SDF-1 binding to CXCR4 promoted transen-
dothelial migration by upregulating the expression of several
integrins, including a4b1 [48]. Indeed, our results showed that a
high percentage of MOPC-315.BM luc+ cells expressed this
important integrin in vitro and in vivo. Of note, MM cells expressed
higher a4b1 levels in the BM than in the spleen. The CD44
receptor also was reportedly involved in MM cell infiltration of the
BM through binding to hyaluronan on BM tissue [34,48]. Several
CD44 splice variants were strongly expressed in patients with
MM; this provided a valuable marker for distinguishing healthy
individuals from those with MM [49]. Our data also demonstrated
high CD44 expression on MOPC-315.BM luc+ cells in vitro and
in vivo. That result suggested that the cell line could interact with
the host environment, and this interaction may regulate surface
molecule expression to coordinate BM homing and retention.
Taken together, our findings of in vivo MM growth and spread
in this MOPC-315.BM luc+ mouse model represented important
criteria for the usefulness of this model in preclinical drug testing.
Our results implied that the cell line retained plasticity, and could
react to outside stimuli, including cell-cell interactions and drug
administration. Furthermore, MOPC-315.BM luc+ cells expressed
important BM homing receptors that are highly relevant in the
human disease and are targeted by currently approved drugs.
Moreover, interactions between MOPC-315.BM luc+ cells and the
surrounding tissues were evidenced by findings of MM-typical
osteolytic lesions and bone remodeling in this mouse model.
Our model provides an advantage over existing animal models,
because it does not rely on the spontaneous onset of B-cell
malignancies. In other animal models, it is difficult to predict the
time of disease onset, disease progression, and the exact disease
subtype [50]. In addition, our model provides the ability to
introduce the tumor at the same time to a large number of
experimental mice. This facilitates meaningful statistical analyses,
and holds great promise for testing the efficacy of a drug.
This orthotopic MM mouse model closely mimicked the late
stages of human MM disease. We demonstrated that it provided
early detection of disease progression, a great advantage over
existing animal models. The non-invasive detection of luc+ MM
cells provided important information on the location of MM cells
in an anatomical context. Therefore, this model represents a
convenient, reproducible platform for preclinical drug testing.
Supporting Information
Figure S1 Representative flow cytometry gating scheme
according to the fluorescence minus one method (FMO).
(A) First, live cells were identified using propidium iodide staining.
Within the live cells the gate for CD138+CD4+ MM cells was set
and applied to all samples within the measurement. Among those
cells the quadrant gate for a4 and a4b7 was set according to the
FMO method. The first FMO sample comprises all sampled
antibodies except for a4 and the quadrant gate was set that a4
unstained cells appeared in the a4 negative quadrant. This gate
was applied to the FMO sample where only a4b7 staining is
missing. The gate was adjusted that a4b7 unstained cells appeared
in the respective negative quadrant. This FMO gate was applied to
all further samples within the measurement. (B) Representative
samples from BM, spleen and the cell line with applied FMO
gates.
(TIF)
Figure S2 Flow cytometric measurement of surface
receptors associated with BM homing and infiltration
of myeloma cells. MOPC-315.BM luc+ myeloma cells were
either directly taken from cell culture or extracted from BM and
spleen as indicated and identified as CD138+CD4+ double positive
cells. a4b7 integrin positive MOPC-315.BM luc+ cells were
identified by flow cytometry as a4+ (CD49d+) and a4b7+ double
positive. Representative quadrant gates or histograms for each
organ and cell line, including unstained fluorescence minus one
(FMO) sample are shown. Graphs state the frequency within
CD138+CD4+ MOPC-315.BM luc+ cells expressing a4b7 (A) or
fold difference of mean fluorescence intensity (MFI) values of
CD62L (B), CCR7 (C), CXCR3 (D) or CCR2 (E) in relation to
the unstained FMO sample.
(TIF)
Figure S3 Verification of in vivo signal localization by
ex vivo BLI. BALB/c wild type mice were injected with 16105
MOPC-315.BM luc+ cells via the tail vein. 19 days after
inoculation tumors were established in all mice and readily
detected by BLI. Then treatment was started ( = day 0 of
treatment). Mice received 5 mg/kg melphalan or mock treatment
(vehicle control) intraperitoneally. One control group of MOPC-
315.BM luc+ tumor bearing mice did not receive any treatment
(untreated). Mice were sacrificed on day +14 of treatment and
organs were prepared for ex vivo BLI. Organs from one
representative mouse per group are shown. In vivo BLI localization
of signals from the liver, spleen and femur/tibia are confirmed.
The signal from the lungs is only detected by ex vivo but not by
in vivo BLI. Organs from the melphalan treatment group displayed
lower signal intensities, indicating lower tumor burden when
compared with untreated or vehicle controls. Therefore, ex vivo
BLI corroborates in vivo data as well as histopathological analysis
of the response to melphalan therapy.
(TIF)
Figure S4 CD31 staining verifies MOPC-315 localiza-
tion inside blood vessels in the lung. (A) Representative
immunofluorescence staining of an IgA+CD4+ MOPC-315.BM
cell within a pulmonary CD31+ vessel in the lung taken from
untreated mice 33 days after MM injection. (B) Negative control
staining, without anti-CD31, anti-IgA and anti-CD4. Only
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secondary strepavidin Alexa546 and DAPI was added. Single
color channels and merge including DAPI are shown. Blue –
CD31, red – IgA, green – CD4, white – DAPI (nuclei). Scale bar is
10 mm. Original magnification 4006/1.30 NA.
(TIF)
Figure S5 In vivo BLI measurements strongly correlate
with MM burden determined by flow cytometry in
spleen and femur/tibia. To additionally verify that non-
invasive BLI data correlate with actual MM load we measured
in vivo BLI signals from the spleen and femur/tibia and
subsequently extracted cells from both organs for FACS analysis.
For FACS MM cells were identified among living cells as
CD4+CD138+. The measured percentage of MM cells infiltrating
the spleen or bone marrow compartments was correlated to
measured BLI signals using a Pearson correlation. Femur/tibia:
Pearson r = 0.9817, p (two tailed) ,0.0001; Spleen: Pearson
r = 0.9757, p (two tailed) ,0.0001.
(TIF)
Figure S6 CD4 expression of MOPC-315.BM luc+ and
the wild type (WT) cell line. MOPC-315.BM luc+ and
MOPC-315 WT cells (obtained from ATCC) were stained for
CD4. Only live cells as determined by propidium iodide staining
were used for the analysis. Both cell lines clearly expressed CD4 to
the same extent. Therefore, the constitutive CD138 and CD4 co-
expression can be considered as a hallmark to uniquely identify
these cells. Grey tinted histogram shows unstained luc+ or WT
cells respectively, black histogram shows CD4 stained cells.
(TIF)
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